Abdullaev, S.P.; Shatokhin, M.N.; Bochkov, P.O.; Tuchkova, S.N.; Loran, O.B.; Abdullaev, S.P.; Mirzaev, K.B.; Sychev, D.A.
Genetic Modulation of Silodosin Exposure and Efficacy: The Role of CYP3A4, CYP3A5, and UGT2B7 Polymorphisms in Benign Prostatic Hyperplasia Management. J. Pers. Med. 2025, 15, 386.
https://doi.org/10.3390/jpm15080386
AMA Style
Abdullaev SP, Shatokhin MN, Bochkov PO, Tuchkova SN, Loran OB, Abdullaev SP, Mirzaev KB, Sychev DA.
Genetic Modulation of Silodosin Exposure and Efficacy: The Role of CYP3A4, CYP3A5, and UGT2B7 Polymorphisms in Benign Prostatic Hyperplasia Management. Journal of Personalized Medicine. 2025; 15(8):386.
https://doi.org/10.3390/jpm15080386
Chicago/Turabian Style
Abdullaev, Shokhrukh P., Maksim N. Shatokhin, Pavel O. Bochkov, Svetlana N. Tuchkova, Oleg B. Loran, Sherzod P. Abdullaev, Karin B. Mirzaev, and Dmitry A. Sychev.
2025. "Genetic Modulation of Silodosin Exposure and Efficacy: The Role of CYP3A4, CYP3A5, and UGT2B7 Polymorphisms in Benign Prostatic Hyperplasia Management" Journal of Personalized Medicine 15, no. 8: 386.
https://doi.org/10.3390/jpm15080386
APA Style
Abdullaev, S. P., Shatokhin, M. N., Bochkov, P. O., Tuchkova, S. N., Loran, O. B., Abdullaev, S. P., Mirzaev, K. B., & Sychev, D. A.
(2025). Genetic Modulation of Silodosin Exposure and Efficacy: The Role of CYP3A4, CYP3A5, and UGT2B7 Polymorphisms in Benign Prostatic Hyperplasia Management. Journal of Personalized Medicine, 15(8), 386.
https://doi.org/10.3390/jpm15080386
